Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc. is a biotechnology company based in Taipei, Taiwan, focused on the research and development of new drugs. Its pipeline includes L606, an inhalation/device combination for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and L608, an inhalation/device combination for pulmonary vascular disease that has completed a Phase I clinical trial. The company was incorporated in 2000 and was formerly known as Pharmosa Limited, changing its name to Pharmosa Biopharm Inc. in October 2016.